Comments
The “Special 301”report from the Office of the United States Trade Representative will be out later this month. The report is a scorecard of sorts by the US of its trading partners, who are graded on their performance in handling Intellectual Property Rights (IPR). The report is keenly watched by domestic industry sectors, especially the pharmaceutical industry, besides infotech and electronics, given the role of IP — patents, trademarks and copyrights. This year, too, a representation from the Indian pharmaceutical industry made its submission to the USTR, making a strong case to take India off the “Priority Watch List”. India is on this 12-member PWL list along with Canada, Russia and China, among others.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.